University of Texas M. D. Anderson Cancer Center Apr 21 2026 An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC). If clinically validated, it could give clinicians much-needed insight into one of the most pressing challenges in oncology. Details of the model, called Path-IO, were presented today